Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br />
Simon J. Harrison, MD, director, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.
The main purpose of the study was to analyze the data from studies of isatuximab with pomalidomide (Pomalyst), and dexamethasone in patients with relapsed or refractory (R/R) multiple myeloma who have cytogenetic abnormalities contributing to their higher risk level. The study showed that the benefit of the regimen was maintained in high-risk patients, even though patients with cytogenetic abnormalities have worse outcomes overall.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More